INTRODUCTION:

A systemic inflammatory illness called rheumatoid arthritis results in persistent inflammation of connective tissue, mostly in the joints, leading to cartilage degradation and synovial growth. Living tissues use inflammation as a defensive mechanism to stave off damage, irritation, and infection. The generation of reactive oxygen species (ROS) by activated neutrophils and macrophages is considered a contributing factor to the process of inflammation extended.¹Rheumatoid arthritis, autoimmune disorders, and other infectious illnesses are brought on by inflammation. The initial Specifically, the synovial membrane that lines the joint cavity will be impacted. The most prevalent kind of arthritis, osteoarthritis, is most frequently seen in the knee joint (6%), followed by the hip joint (3%). Joint pain is one of the clinical signs. stiffness and edema that might get worse with exercise or rest. Numerous investigations have suggested that synovial inflammation might be a key factor in the etiology of OA.²Synoviocytes that are activated, macrophages, and the articular cartilage itself generate Numerous novel mediators, including as TNF-a, IL-2, and enzymes, have been discovered by researchers to either directly or indirectly contribute to the persistence of RA. Protein denaturation has been identified as the cause of inflammation in arthritis. Indications are that when living tissues are injured, inflammation results. This is characterized by redness, pain, heat, swelling, as well as loss of function in the affected area. Disruption of the electrostatic, hydrogen, hydrophobic and disulphide bonds in the protein structure occurs. In addition, a complex array of enzyme activation, mediator release, cell migration, tissue breakdown and repair, occur, causing the protein to lose its molecular conformation and functions or become denatured. It is therefore deduced that, compounds which are able to prevent these changes and inhibit thermally or heat induced protein denaturation, have potential therapeutic value as anti-inflammatory agents. Although the exact cause of rheumatoid arthritis is unknown, it is thought to be brought on by a combination of Exposure to environmental variables and genetic vulnerability. Steroid medications, immunosuppressants, and non-steroidal anti-inflammatory drug therapy are commonly used to treat rheumatoid arthritis.³Environmental risk factors are major determinants of population health and are crucial to the management of RA. Similar to other illnesses, RA is associated with smoking at its onset or worsening. By coincidence, research with a different goal revealed the first proof linking smoking to an increased risk of RA.⁴Nonetheless, gastrointestinal issues, immunodeficiencies, and humoral abnormalities are among the numerous adverse effects of these medications that are known to exist. As a result, efforts must be made to find therapeutic substances that are suitable for continuous usage. According to research, between 60 and 90 percent of Americans with rheumatoid arthritis have utilized complementary and alternative medicine (CAM), primarily herbal therapy.⁵

Pathogenesis T, B, and monocyte infiltration of the synovial membrane in several joints is a hallmark of RA. Endothelial cell activation occurs before to this process; neovascularization, or the formation of new blood vessels, is another defining feature of RA synovitis.⁶ A hyperplastic layer of synovial lining results from the expansion of cells that resemble synovial fibroblasts and macrophages. Known by many as the "pannus," this enlarged synovial membrane invades the periarticular bone at the causes bone erosions and cartilage degeneration at the cartilage-bone interface. Pro-inflammatory cytokines, such as tumor necrosis factor (TNF) and interleukin (IL)-6, induce molecules like matrix metalloproteinases, prostaglandins, and receptor activator of nuclear factor κB ligand (RANKL), which mediate disease signs and symptoms like pain, swelling, and cartilage and bone degradation.Six⁷

Fig no 1. Pathogenesis of rheumatoid arthritis

Pro-inflammatory cytokines, such as tumor necrosis factor (TNF) and interleukin (IL)-6, induce molecules like matrix metalloproteinases, prostaglandins, and receptor activator of nuclear factor κB ligand (RANKL), which mediate disease signs and symptoms like pain, swelling, and cartilage and bone degradation. Six In the synovial membrane, stimulation by RANKL, TNF, and IL-6 produces osteoclasts, which in turn encourages bone degradation⁷.The manifestation of the clinical illness is the outcome of these molecular and cellular processes. Increased joint edema is inherently linked to the progression of joint injury. There is no recognized cause of RA. Nonetheless, RA is influenced by both environmental and genetic variables. RA is linked to several gene loci (Box). But certain HLA class II antigens, including HLA-DRB1*01 and HLA-DRB1*04, have the "shared" epitope—a five-amino acid stretch in the area accountable for T lymphocyte antigen presentation—and are most closely connected to RA.⁸ Genes with weaker connections (Box) could also be involved, particularly through interactions between genes and the environment. Among the environmental risk factors for RA are: viral infections, periodontitis, and features of the gut, mouth, and pulmonary microbiome. In terms of the microbiome, Prohormones gingivitis, linked to periodontitis, and Prevotella species, which are increased in the gastrointestinal tract in early RA, may play a part in pathogenesis. According to recent research, germs may move from the stomach to tissues, triggering autoimmune diseases and inflammation.⁹ Inflammatory responses are also encouraged by epigenetic changes including histone acetylation and DNA methylation. By forming neoepitopes of different autologous proteins (such as collagen, vimentin, and fibrinogen), post translational protein modifications like citrullination of arginine by peptidyl arginine deiminase or carbamylation of lysine contribute to breaking immunological tolerance. This results in the formation of autoantibodies against autoantigens (such as anticitrullinated peptide antibodies [ACPAs]), antibodies to IgG (rheumatoid factor [RF]), nuclear antigens, or autoantigens that cross-react with bacterial or viral antigens. Prevotella and the Epstein-Barr virus, for example. These autoantibodies have the ability to assemble into immunological complexes that might activate complement, hence escalating inflammatory reactions. Thirteen ACPAs and RF together can stimulate a significant inflammatory response, although ACPAs by alone only slightly inflame the body.^10,11 RFs increase the inflammatory response triggered by immune complexes and complement activation, as well as the immune complexes generated by ACPAs.1. Autoantibodies form in advance of symptoms and indications. This phase, known as "pre-RA," might extend for a duration of less than a year or more than ten years. How long it took for RA to manifest symptoms and the autoantibody profile are connected. People who express ACPAs alone experience symptoms 5 to 10 years after the autoantibody arises, but those who express ACPAs, RF, and elevated C-reactive protein (CRP) experience symptoms a few months after the arrival of the third of these components.27In certain patients with pre-RA, subtle inflammatory alterations in the synovium have been seen. Histology-identified overt inflammatory alterations are not necessarily correlated with clinical signs and symptoms, even in cases with established RA.^12,13

Clinical Presentation:

RA is a polyarticular symmetric illness that affects both sides of the joint. Pain and swelling in the hands and foot joints are common symptoms of RA patients. Mainly the wrists, metacarpophalangeal, metatarsophalangeal, and proximal interphalangeal joints are swollen. Along with this, there is typically morning joint stiffness that lasts for many hours, if not longer than thirty minutes. Unlike the "hard" (bony) swellings of osteoarthritis, the swelling is usually "soft" due to synovitis and diffusion.

Instead of affecting the whole digit ("sausage digit") as is the case with psoriatic arthritis, swelling in the fingers is centered around the joint (fusiform). It is possible for both big and small joints to be damaged, although seldom the distal interphalangeal joints. The metacarpophalangeal and other small joints. Extra-articular symptoms may appear if RA is not well managed. Rheumatoid nodules, which are hard subcutaneous lumps that are located around bony prominences like the elbow, are the most common. Rheumatoid vasculitis is a more severe manifestation that mostly affects the skin and causes necrotizing inflammation of small or medium-sized arteries. sometimes arteries in other organs, as well as the vasa nervorum. Multiple comorbidities may influence patients with RA. Heart disease is the main cause of mortality for individuals with RA and a typical outcome of persistent inflammation. Cardiovascular disease and disease activity are more strongly correlated in RA patients than they are with conventional cardiovascular risk factors. Utilizing certain biologic agents decreases. cardiovascular risk. Interstitial lung disease may be a manifestation of RA or may be a complication of RA therapies, such as methotrexate and leflunomide. ¹⁴

MATERIALS AND METHODS:

In July, shed dried stem of Malachra capitata (L.) L. were obtained from the Bhusawal local region in the Jalgaon district of India. Soon after being purchased, the stem were mechanically processed into a coarse powder, dried, and stored in air tight container for application in the research.

Fig no 2. Malachra capitata

Chemicals:

Acquired methotrexate (Folitrax) from the Cipla Corporation. Additional reagents and substances utilized in the investigation were analytical grade and obtained from authorized companies.

Preparation of extract:

A soxhlet device was filled with three grams (3g) of dried and crushed Malachra capitata stem powder. For six hours, extraction was done using 150 milliliters of the suitable solvent. Following extraction, a Solvent was removed using a rotating vacuum evaporator set at 40 ◦C. In this experiment, 70% ethanol and four solvents were utilized.¹⁵

Fig no 3. Soxhlet extraction

Evaluation of in vitro anti-arthritic activity: Protein degradation using egg alpha-amylase:

Two milliliters of fresh hen's egg albumin (0.2ml), 2.8 milliliters of phosphate buffered saline (PBS, pH 6.4), and two milliliters of Malachra capitata extract at various quantities made up there to achieve 100, 200, 400 & 800µg/ml final concentrations. As a control, a comparable volume of double-distilled water was used. After that, the solutions were heated for five minutes at 70ºC after being incubated for fifteen minutes at 37±2ºC in a BOD incubator. Their absorbance was measured at 660 nm upon cooling. The benchmark medication of reference was methotrexate.¹⁶

Fig no 4. Protein degradation using egg alpha-amylase

Fig no 5. Albumin protein denaturation

FORMULA:

Using the following formula, the percentage inhibition of protein denaturation was determined: (Abs control - Abs sample) X 100/Abs control equals percentage inhibition.

BOVINE SERUM-BASED PROTEIN DENATURATION ALBUMIN:

One percent of an aqueous solution of bovine albumin and various quantities of an Ethanolic extract of Malachra capitata made up the reaction mixture. The specimens were heated for 20 minutes at 57°C after being incubated for 20 minutes at 37°C. The samples were cooled, and the turbidity absorbance was measured at 660nm.

FORMULA:

The percentage of protein denaturation inhibition was computed using the formula below:

(Abs control - Abs sample) X 100/Abs control equals percentage inhibition.

RESULT AND DISCUSSION:

Malachra capitata ethanolic extracts were tested for their ability to prevent egg and bovine albumin from becoming denaturated. Tables 1 and 2 provide a summary of the findings. By inhibiting protein denaturation, the extraction of herbal extract demonstrated significant anti-arthritic action at 100–600 µg/ml. By contrasting the herbal extract with the conventional methotrexate, the effects were investigated. Protein denaturation is one of the causes of rheumatoid arthritis, according to several studies, and it leads to the development of autoantigens in rheumatoid arthritis.¹⁶

Table 1: Effect of mc ethanolic extract on protein denaturation (fresh egg albumin)

Treatment	Concentration (µg/ml)	Absorbance (at 660 nm)	Percentage of Protien inhibition (%)
Control		0.677
MC Ethanolic extract	100	0.1846	96.54
	200	0.1355	98.75
	400	0.1176	99.88
	600	0.0716	99.35
	800	0.0106	99.38
Methotrexate	100	0.0396	97.70

Table 2: Effect mc ethanolic extract on protein denaturation (bovine serum albumin)

Treatment	Concentration (µg/ml)	Absorbance (at 660 nm)	Percentage of Protien inhibition (%)
Control		0.684
MC Ethanolic extract	100	0.1842	73.07
	200	0.1462	78.62
	400	0.1182	82.71
	600	0.0804	88.24
	800	0.0496	92.74
Methotrexate	100	0.0288	95.78

Fig no 6. In-vitro anti-arthritic activity using egg albumin

Fig no 7. In-vitro anti-arthritic activity using bovine serum albumin

Molecular Docking:

In recent years, molecular docking has emerged as a crucial component of in-silico drug development. This method involves predicting the atomic-level1 interaction between a tiny chemical and a protein. This makes it possible for scientists to examine how tiny compounds, like nutraceuticals, behave within a target protein's binding region and comprehend the basic biochemical mechanism underpinning this interaction. approach is structure-based and needs a high-resolution 3D model of the target protein, which can be acquired using methods such as Cryo-Electron Microscopy3-5, Nuclear Magnetic Resonance Spectroscopy, or X-ray crystallography. Numerous molecular docking algorithms and computational tools are available, both for free and for a cost.

The molecular docking of active constituent was conducted by using SWISSDOCK to evaluate in silico antiarthritic activity activity of the isolated metabolites the X-ray crystal structure of active cox2 inhibitor protein 2QVD, as proposed molecular target, was obtained from the RCSB protein data bank (https://doi.org/10.2210/pdb2QVD/pdb). water molecules and ligands which are not involved in the binding were removed. The protein was prepared using Protonate 3D protocol in MOE with default options. And then molecular docking was carried out by obtaining docking score of three active constituents present in Malachra capitata extract. The molecular docking was performed for chemical constituent Linolenic acid that has anti-arthritic proporerty. The compound name Linolenic acid has docking score -7.00 and its binding affinity was found to be -833.12.

Formula for binding affinity of ligand and protein:

Binding Affinity Δ =

Total energy of complex – (Uncomplexed ΔG. protein + Uncoplexed ΔG ligand

Fig no 8 Interaction between Linolic acid and PDB(2QVD)

CONCLUSION:

The goal of the current study was to determine if an ethanolic extract of Malachra capitata stem might treat arthritis. Protein denaturation and stabilization.To verify activities, HRBC membrane lysis triggered by hypotonicity was performed. Our current research on Malachra capitata in vitro experiments shows notable and dose-dependent ant arthritic activity. This action could be caused by the active ingredients present in the ethanolic extract. To determine the mode of action of Malachra capitata ethanolic extract, more research has to be done.

In silico results shows the major binding affinity for Linolenic acid which has major anti-arthritic activity present in Malachra capitata stem extract shows their affinity for optimized PDB 2QVD.From these results we concluded that Malachra capitata posses strong anti-arthritic proporerty.

REFERENCES:

1. Joshi DG, Kumar R. In vitro protein denaturation and membrane stabilizing anti-arthritic activity of aqueous extracts of bark of Ficus benghalensis L. against methotrexate. The Pharma Innovation Journal. 2021; 10(4): 689.

2. Ghosh S, Saha K, Dasgupta SC, Gomes A. In vitro and In vivo Anti-Arthritic and Anti-Inflammatory Activity of Bungarus Fasciatus Venom. J Toxins. 2015; 2(1): 5.

3. Kandikattu K. Evaluation of anti-inflammatory activity of Canthium parviflorum by in-vitro method. Indian Journal of Research in Pharmacy and Biotechnology. 2013; 1(5): 729-730.

4. Andrei F. R. Management of Rheumatoid Arthritis: An Overview MDPI Cells. 2021; 10: 2857.

5. Godswill N A. Evaluation of Costusafer Ker Gawl. in vitro anti-inflammatory activity and its chemical constituents identified using gas chromatography-mass spectrometry analysis. Journal of Coastal Life Medicine. Journal of Coastal Life Medicine. 2015; 3(2): 132-138. DOI:10.12980/JCLM.3.2015APJTB-2014-0186

6. Derksen V. F. A. M. The role of autoantibodies in the pathophysiology of rheumatoid arthritis Semin. Immunopathol. 2017; 39: 437–4.

7. Daniel A. Diagnosis and Management of Rheumatoid Arthritis A Review. Clinical Review Education. JAMA. 2018; 320(13):1360- 1372.

8. Viatte S., Barton A. Genetics of rheumatoid arthritis susceptibility, severity, and treatment response. Semin Immunopathol. 2017; 39: 395–408.

9. Rogers J, Dieppe P. Skeletal palaeopathology and the rheumMatic diseases: where are we now? Ann Rheum Dis. 1990; 49: 885–88

10. Redlich, K., Smolen, J. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov. 2012; 11: 234–250. https://doi.org/10.1038/nrd3669.

11. Romão VC, Fonseca JE. Etiology and Risk Factors for Rheumatoid Arthritis: A State-of-the-Art Review. Front Med (Lausanne). 2021; 8: 689698. doi: 10.3389/fmed.2021.689698.

12. EI- Gabalawy, H S, Robinson D B. Non-HLA genes modulate the risk of rheumatoid arthritis associated with HLA-DRB1 in susceptible North American Native population. Genes Immun. 2011; 12: 568–574.

13. Zhao Li et al. Associations between CCL21 gene polymorphisms and susceptibility to rheumatoid arthritis: a metaanalysis. Rheumatol Int. 2017; 37: 1673–1681.

14. Berglin E, Ohansson T J, Sundin U. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset, Annals of the Rheumatic Diseases. 2006; 65: 453- 458.

15. Chandra S, Chatterjee P, Dey P, Bhattacharya S. Evaluation of in vitro anti-inflammatory activity of coffee against the denaturation of protein. Asian Pac. J. Trop. Biomed. 2012: S178 S180.

16. Pavithra TK, Smitha KP, Kulashekar KS, and Ashok Kumar BS. Evaluation of in vitro Anti-Arthritic Activity of Vitex negundo against the Denaturation of Protein. Int. J. Curr. Microbiol. App. Sci. 2015; 4(9): 87-90.

Received on 31.05.2024 Revised on 26.11.2024

Accepted on 05.02.2025 Published on 01.12.2025

Available online from December 06, 2025

Research J. Pharmacy and Technology. 2025;18(12):5833-5838.

DOI: 10.52711/0974-360X.2025.00841

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.